Analysis on the efficacy and safety of chemotherapy combined with or without bevacizumab after CRS+HIPEC in patients with malignant peritoneal mesothelioma: a single-center retrospective study
Our exploratory findings suggest that bevacizumab combined with pemetrexed/platinum-based chemotherapy may be a therapeutic option for MPM patients after CRS+HIPEC; however, a prospective, randomized controlled clinical study is needed to validate our findings.
Authors
- Xin-Bao Li (ORCID: https://orcid.org/0000-0003-1253-8361)
- Xin-Li LIANG
- Xinjing Zhang (ORCID: https://orcid.org/0000-0002-8981-8946)
- Yong Li (ORCID: https://orcid.org/0000-0003-4038-0493)
- Zikun Yang (ORCID: https://orcid.org/0009-0003-1099-9145)
- Songlin An (ORCID: https://orcid.org/0000-0002-0862-5377)
- He-Liang Wu
- Yan-Dong Su
Institutions
- Capital Medical University (CN)
- Beijing Tsinghua Chang Gung Hospital (CN)
- Beijing Shijitan Hospital (CN)
- Tsinghua University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-02-03
- DOI
- https://doi.org/10.3389/fonc.2026.1733967
- Primary Topic
- Intraperitoneal and Appendiceal Malignancies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Beijing Municipal Administration of Hospitals